Literature DB >> 11157725

Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice.

S Konstantinides1, K Schäfer, T Thinnes, D J Loskutoff.   

Abstract

BACKGROUND: The origin and contribution of plasminogen activator inhibitor-1 (PAI-1) and its cofactor vitronectin (VN) to arterial thrombosis/thrombolysis in vivo is controversial. METHODS AND
RESULTS: Ferric chloride was used to induce carotid artery injury in 97 wild-type (WT), 84 PAI-1-/-, and 84 VN-/- mice. Complete thrombotic occlusion was observed in 70% of PAI-1-/- mice versus 92% of WT (P:<0.001) and 87% of VN-/- (P:=0.015) mice. In vessels that occluded, mean times to occlusion were significantly longer in PAI-1-/- than in WT or VN-/- mice. The initial thrombotic response of VN-/- mice was similar to that of WT mice, but their thrombi were unstable and frequently embolized. As a result, the patency rate of carotid vessels 30 minutes after injury was as high in VN-/- mice (36%) as in PAI-1-/- mice (which demonstrate progressive thrombolysis) and significantly higher than that of WT mice (12%; P:=0.013). Histochemical and reverse transcription-polymerase chain reaction studies revealed an early upregulation of PAI-1 mRNA and protein expression in the thrombus and the vessel wall, which persisted for >/=1 week. VN protein also accumulated after injury, but VN mRNA levels remained low at all times.
CONCLUSIONS: PAI-1 and VN participate in the thrombotic response to arterial injury by preventing premature thrombus dissolution and embolization. The accumulation of PAI-1 in the thrombus/vessel wall after injury may result, at least in part, from local synthesis, whereas the VN protein appears to be derived from plasma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157725     DOI: 10.1161/01.cir.103.4.576

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  43 in total

1.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

Review 2.  Endothelial Repair and Regeneration Following Intimal Injury.

Authors:  Belay Tesfamariam
Journal:  J Cardiovasc Transl Res       Date:  2016-01-21       Impact factor: 4.132

3.  The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation.

Authors:  Brian G Petrich; Per Fogelstrand; Anthony W Partridge; Nima Yousefi; Ararat J Ablooglu; Sanford J Shattil; Mark H Ginsberg
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Serum vitronectin levels in patients with Behçet's disease.

Authors:  Ali Yalçındağ; Aslıhan Uzun; F Nilüfer Yalçındağ; Namık Delibaş
Journal:  Inflamm Res       Date:  2012-07-19       Impact factor: 4.575

5.  Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity.

Authors:  S Konstantinides; K Schäfer; S Koschnick; D J Loskutoff
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

6.  Exchange protein directly activated by cAMP plays a critical role in regulation of vascular fibrinolysis.

Authors:  Xi He; Aleksandra Drelich; Shangyi Yu; Qing Chang; Dejun Gong; Yixuan Zhou; Yue Qu; Yang Yuan; Zhengchen Su; Yuan Qiu; Shao-Jun Tang; Angelo Gaitas; Thomas Ksiazek; Zhiyun Xu; Jia Zhou; Zongdi Feng; Maki Wakamiya; Fanglin Lu; Bin Gong
Journal:  Life Sci       Date:  2019-02-07       Impact factor: 5.037

7.  Comparative anti-thrombotic activity and haemorrhagic adverse effect of nattokinase and tissue-type plasminogen activator.

Authors:  Haiyu Guo; Young-Hwan Ban; Yeseul Cha; Eun Suk An; Jieun Choi; Da Woom Seo; Dongsun Park; Ehn-Kyoung Choi; Yun-Bae Kim
Journal:  Food Sci Biotechnol       Date:  2019-05-27       Impact factor: 2.391

8.  β₂-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis.

Authors:  Sergio E Chiarella; Saul Soberanes; Daniela Urich; Luisa Morales-Nebreda; Recep Nigdelioglu; David Green; James B Young; Angel Gonzalez; Carmen Rosario; Alexander V Misharin; Andrew J Ghio; Richard G Wunderink; Helen K Donnelly; Kathryn A Radigan; Harris Perlman; Navdeep S Chandel; G R Scott Budinger; Gökhan M Mutlu
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

9.  Does plasmin have anticoagulant activity?

Authors:  Jane Hoover-Plow
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

10.  Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease.

Authors:  Hakan Ekmekci; Huseyin Sonmez; Ozlem B Ekmekci; Zeynep Ozturk; Nergiz Domanic; Emine Kokoglu
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.